Luciana Molinero to Biomarkers, Tumor
This is a "connection" page, showing publications Luciana Molinero has written about Biomarkers, Tumor.
Connection Strength
0.576
-
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol. 2024 06; 263(2):190-202.
Score: 0.129
-
Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021 06 25; 12(1):3969.
Score: 0.107
-
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274.
Score: 0.095
-
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072.
Score: 0.093
-
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 05 01; 29(9):1698-1707.
Score: 0.030
-
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1733-1743.
Score: 0.027
-
Enrichment of circulating tumor-derived extracellular vesicles from human plasma. J Immunol Methods. 2021 03; 490:112936.
Score: 0.026
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
Score: 0.024
-
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
Score: 0.023
-
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328.
Score: 0.022